Can you take Despec Drops with Thiopental?
1 drug interaction and 21 additional warnings found for the following 2 drugs:
- Despec Drops (dextromethorphan/guaifenesin/pseudoephedrine)
- thiopental
Drug interactions
Moderate drug interactions
Moderate:
dextromethorphan thiopental
Applies to: Despec Drops (dextromethorphan / guaifenesin / pseudoephedrine) and thiopental
Using dextromethorphan together with thiopental may increase side effects such as:
- dizziness
- drowsiness
- confusion
- difficulty concentrating
Some people, especially the elderly, may also experience impairment in thinking, judgment, and motor coordination.
What to do: You should avoid or limit the use of alcohol while being treated with these medications. Also avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medications affect you.
Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Major food/lifestyle interactions
Major:
thiopental Alcohol (Ethanol)
Applies to: thiopental
Ask your doctor before using thiopental together with ethanol (alcohol), this can add to dizziness, drowsiness and other side effects of thiopental.
Be careful if you drive or do activities that require you to be awake and alert.
Talk with your doctor before using any medications together, or drinking alcohol with thiopental.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Moderate food/lifestyle interactions
Moderate:
dextromethorphan Food/Lifestyle
Applies to: Despec Drops (dextromethorphan / guaifenesin / pseudoephedrine)
Alcohol can increase the nervous system side effects of dextromethorphan such as:
- dizziness
- drowsiness
- difficulty concentrating
Some people may also experience impairment in thinking and judgment.
You should avoid or limit the use of alcohol while being treated with dextromethorphan.
Do not use more than the recommended dose of dextromethorphan, and avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medication affects you.
Talk to your doctor or pharmacist if you have any questions or concerns.
Moderate:
pseudoephedrine Caffeine
Applies to: Despec Drops (dextromethorphan / guaifenesin / pseudoephedrine)
Both pseudoephedrine and caffeine can increase blood pressure and heart rate, and combining them may enhance these effects.
Talk to your doctor before using these medications, especially if you have a history of high blood pressure or heart disease. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications.
Contact your doctor if your condition changes or you experience increased side effects.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Disease interactions
18 potential interactions Applies to: 18 conditions, including Asthma, Benign Prostatic Hyperplasia, Anemia, Hyperthyroidism, and Myasthenia Gravis.
Adrenal Insufficiency
Major:
thiopental
Thiopental has a major potential interaction with Adrenal Insufficiency.
Thiopental should not be used in patients with Addison disease or any adrenal gland disorder.
Anemia
Major:
thiopental
Thiopental has a major potential interaction with Anemia.
Thiopental should not be used in patients with severe anemia.
Asthma
Major:
thiopental
Thiopental has a major potential interaction with Asthma.
Thiopental should not be used in patients with asthma as it can lead to intraoperative bronchospasm which can be catastrophic.
Benign Prostatic Hyperplasia
Moderate:
Despec Drops
The pseudoephedrine in Despec Drops has a moderate potential interaction with Benign Prostatic Hyperplasia.
Sympathomimetic agents may cause or worsen urinary difficulty in patients with prostate enlargement due to smooth muscle contraction in the bladder neck via stimulation of alpha-1 adrenergic receptors. Therapy with sympathomimetic agents should be administered cautiously in patients with hypertrophy or neoplasm of the prostate.
Cardiovascular Conditions and Disorders
Major:
Despec Drops
The pseudoephedrine in Despec Drops has a major potential interaction with Cardiovascular Conditions and Disorders.
Sympathomimetic agents may cause adverse cardiovascular effects, particularly when used in high dosages and/or in susceptible patients. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta- 1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, coronary occlusion, cerebral vasculitis, myocardial infarction, cardiac arrest, and death have been reported. Some of these agents, particularly ephedra alkaloids (ephedrine, ma huang, phenylpropanolamine), may also predispose patients to hemorrhagic and ischemic stroke. Therapy with sympathomimetic agents should generally be avoided or administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders. These agents should not be used in patients with severe coronary artery disease or severe/uncontrolled hypertension.
Cerebrovascular Insufficiency
Major:
Despec Drops
The pseudoephedrine in Despec Drops has a major potential interaction with Cerebrovascular Insufficiency.
Sympathomimetic agents may cause adverse cardiovascular effects, particularly when used in high dosages and/or in susceptible patients. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta- 1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, coronary occlusion, cerebral vasculitis, myocardial infarction, cardiac arrest, and death have been reported. Some of these agents, particularly ephedra alkaloids (ephedrine, ma huang, phenylpropanolamine), may also predispose patients to hemorrhagic and ischemic stroke. Therapy with sympathomimetic agents should generally be avoided or administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders. These agents should not be used in patients with severe coronary artery disease or severe/uncontrolled hypertension.
Diabetes Mellitus
Moderate:
Despec Drops
The pseudoephedrine in Despec Drops has a moderate potential interaction with Diabetes Mellitus.
Sympathomimetic agents may cause increases in blood glucose concentrations. These effects are usually transient and slight but may be significant with dosages higher than those normally recommended. Therapy with sympathomimetic agents should be administered cautiously in patients with diabetes mellitus. Closer monitoring of blood glucose concentrations may be appropriate.
Gastrointestinal Obstruction
Moderate:
Despec Drops
The pseudoephedrine in Despec Drops has a moderate potential interaction with Gastrointestinal Obstruction.
The extended-release formulation of pseudoephedrine (Sudafed 24 Hour) contains a non-deformable material. There have been rare reports of obstructive symptoms in patients with known strictures following the ingestion of similar sustained-release products. Therapy with the extended-release formulation of pseudoephedrine should be administered cautiously in patients with preexisting severe gastrointestinal narrowing or obstruction, whether pathologic or iatrogenic.
Glaucoma/Intraocular Hypertension
Moderate:
Despec Drops
The pseudoephedrine in Despec Drops has a moderate potential interaction with Glaucoma/Intraocular Hypertension.
Sympathomimetic agents can induce transient mydriasis via stimulation of alpha-1 adrenergic receptors. In patients with anatomically narrow angles or narrow-angle glaucoma, pupillary dilation can provoke an acute attack. In patients with other forms of glaucoma, mydriasis may occasionally increase intraocular pressure. Therapy with sympathomimetic agents should be administered cautiously in patients with or predisposed to glaucoma, particularly narrow-angle glaucoma.
Hyperthyroidism
Major:
Despec Drops
The pseudoephedrine in Despec Drops has a major potential interaction with Hyperthyroidism.
Sympathomimetic agents may cause adverse cardiovascular effects, particularly when used in high dosages and/or in susceptible patients. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta- 1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, coronary occlusion, cerebral vasculitis, myocardial infarction, cardiac arrest, and death have been reported. Some of these agents, particularly ephedra alkaloids (ephedrine, ma huang, phenylpropanolamine), may also predispose patients to hemorrhagic and ischemic stroke. Therapy with sympathomimetic agents should generally be avoided or administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders. These agents should not be used in patients with severe coronary artery disease or severe/uncontrolled hypertension.
Liver Disease
Major:
thiopental
Thiopental has a major potential interaction with Liver Disease.
Thiopental should not be used in patients with liver dysfunction. The distribution half-life and the duration of the drug action will be prolonged.
Myasthenia Gravis
Major:
thiopental
Thiopental has a major potential interaction with Myasthenia Gravis.
Thiopental should not be used in patients with myasthenia gravis as it can prompt myasthenic crises.
Phenylketonuria
Moderate:
Despec Drops
The pseudoephedrine in Despec Drops has a moderate potential interaction with Phenylketonuria.
Chewable products frequently may contain aspartame, which is metabolized in the gastrointestinal tract to phenylalanine. Sudafed (brand of pseudoephedrine) chewable 15 mg tablets provide the equivalent of 0.78 mg of phenylalanine per each tablet. The aspartame/phenylalanine content should be considered when this and similar products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).
Pheochromocytoma
Major:
Despec Drops
The pseudoephedrine in Despec Drops has a major potential interaction with Pheochromocytoma.
Sympathomimetic agents may cause adverse cardiovascular effects, particularly when used in high dosages and/or in susceptible patients. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta- 1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, coronary occlusion, cerebral vasculitis, myocardial infarction, cardiac arrest, and death have been reported. Some of these agents, particularly ephedra alkaloids (ephedrine, ma huang, phenylpropanolamine), may also predispose patients to hemorrhagic and ischemic stroke. Therapy with sympathomimetic agents should generally be avoided or administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders. These agents should not be used in patients with severe coronary artery disease or severe/uncontrolled hypertension.
Porphyria
Major:
thiopental
Thiopental has a major potential interaction with Porphyria.
The use of thiopental is contraindicated in patients with porphyria.
Prostate Tumor, Benign
Moderate:
Despec Drops
The pseudoephedrine in Despec Drops has a moderate potential interaction with Prostate Tumor, Benign.
Sympathomimetic agents may cause or worsen urinary difficulty in patients with prostate enlargement due to smooth muscle contraction in the bladder neck via stimulation of alpha-1 adrenergic receptors. Therapy with sympathomimetic agents should be administered cautiously in patients with hypertrophy or neoplasm of the prostate.
Renal Dysfunction
Major:
thiopental
Thiopental has a major potential interaction with Renal Dysfunction.
Thiopental should not be used in patients with renal impairment. If so, the dose needs to be considerably reduced.
Thyroid Disease
Major:
thiopental
Thiopental has a major potential interaction with Thyroid Disease.
Thiopental should not be used in patients with thyroid disorder as it influences thyroid metabolism.
Report options
More resources
Despec Drops
A total of 546 drugs are known to interact with Despec Drops.
- Despec drops is in the drug class upper respiratory combinations.
- Despec drops is used to treat Cough and Nasal Congestion.
thiopental
A total of 278 drugs are known to interact with thiopental.
- Thiopental is in the drug class general anesthetics.
- Thiopental is used to treat the following conditions:
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.